FDA To Regulate Direct-To-Consumer Genetic Tests
This article was originally published in The Tan Sheet
Executive Summary
FDA sent letters to five genetic testing firms requesting pre-market submissions for the companies' already-marketed services, citing the need to prove that direct-to-consumer genetic assays are analytically and clinically accurate
You may also be interested in...
FDA, 23andMe Open Up Market Pathway For DTC Genetics
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
FDA, 23andMe Open Up Market Pathway For DTC Genetics
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
FDA Points To Premarket Clearance For Direct-To-Consumer Genetic Tests
FDA tells direct-to-consumer genetic testing company 23andMe that it should immediately stop marketing its Personal Genome Service in a strongly worded, lengthy warning letter that experts say could provide guidance across the sector. The firm says it will address the agency’s concerns.